Abstract

The use of cystatin C alone or in combination with creatinine strengthens the association between the eGFR and the risks of death and end-stage renal disease across diverse populations. (Funded by the National Kidney Foundation and others.).

Keywords

Cystatin CRenal functionMedicineCreatinineKidney diseaseInternal medicineCystatinPopulationConfidence intervalUrologyEndocrinologyGastroenterologyEnvironmental health

Affiliated Institutions

Related Publications

Publication Info

Year
2013
Type
review
Volume
369
Issue
10
Pages
932-943
Citations
922
Access
Closed

External Links

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

922
OpenAlex

Cite This

Michael G. Shlipak, Kunihiro Matsushita, Johan Ärnlöv et al. (2013). Cystatin C versus Creatinine in Determining Risk Based on Kidney Function. New England Journal of Medicine , 369 (10) , 932-943. https://doi.org/10.1056/nejmoa1214234

Identifiers

DOI
10.1056/nejmoa1214234